Stock Research: IDEAYA Biosciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

IDEAYA Biosciences

NSQ:IDYA US45166A1025
16
  • Value
    18
  • Growth
    6
  • Safety
    Safety
    16
  • Combined
    1
  • Sentiment
    85
  • 360° View
    360° View
    16
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 16 (better than 16% compared with alternatives), overall professional sentiment and financial characteristics for the stock IDEAYA Biosciences are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for IDEAYA Biosciences. The consolidated Sentiment Rank has a good rank of 85, which means that professional investors are more optimistic about the stock than for 85% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 18, which means that the share price of IDEAYA Biosciences is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 6, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 6% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 16 which means that the company has a riskier financing structure than 84% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 n/a n/a n/a
Growth
6 n/a n/a n/a
Safety
Safety
16 n/a n/a n/a
Sentiment
85 n/a n/a n/a
360° View
360° View
16 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
34 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
79 n/a n/a n/a
Sentiment
85 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 n/a n/a n/a
Growth
6 n/a n/a n/a
Safety Safety
16 n/a n/a n/a
Combined
1 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 n/a n/a n/a
Price vs. Earnings (P/E)
63 n/a n/a n/a
Price vs. Book (P/B)
38 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
18 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
7 n/a n/a n/a
Profit Growth
12 n/a n/a n/a
Capital Growth
53 n/a n/a n/a
Stock Returns
49 n/a n/a n/a
Growth
6 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
55 n/a n/a n/a
Refinancing
53 n/a n/a n/a
Liquidity
5 n/a n/a n/a
Safety Safety
16 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to IDEAYA Biosciences and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: